Clinical Trial Update: Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction [Phase 1]

View source ↗

Summary

Phase 1 study evaluating Erlotinib in adults with unresectable hepatocellular carcinoma and liver dysfunction has completed, reporting initial safety and tolera…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer | Phase 1 | Status: COMPLETED